Barcode Nanotech
Target-specific nanoparticles for next generation RNA therapies
Company Overview
Snapshot
Founded in March 2017 by Ronen Eavri, Avi Schroeder, and Annie Sabbah, Barcode Nanotech operates with 1–10 employees. The company has raised a total of $7.6M across 5 funding rounds from 4 investors. In August 2022, NGT HealthCare II participated in a funding round.
Business overview
Barcode Nanotech specializes in developing targeted delivery vehicles for next-generation RNA/DNA therapeutics, addressing the critical need for precise and safe delivery to target organs and cells. The company's proprietary Lipid Nanoparticles (LNPs) are designed to selectively reach target cells and tissues while protecting RNA molecules from degradation. Barcode Nanotech utilizes an AI-based platform for designing these LNPs and a high-throughput in vivo screening platform for rapid testing and optimization. The company focuses on selective indications such as hard-to-treat cancers, metabolic diseases, and fibrosis, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In June 2017, Barcode Nanotech secured early investment from NGT3 and the Israel Innovation Authority, signaling strong foundational support for its innovative approach to RNA/DNA therapeutic delivery. This initial backing highlights the perceived potential of its proprietary lipid nanoparticle technology and molecular barcoding platform to address significant challenges in targeted drug delivery, particularly for complex diseases like cancer and metabolic disorders. For investors, this early validation from key players in the Israeli innovation ecosystem underscored the company's promise in a high-growth segment of the biotechnology market.
Log in to access full profile ›Company Intelligence Q&A
- When was Barcode Nanotech founded?
- Barcode Nanotech was founded in March 2017 by Ronen Eavri, Avi Schroeder, and Annie Sabbah.
- What is Barcode Nanotech's primary focus?
- Barcode Nanotech focuses on developing target-specific nanoparticles for next-generation RNA therapies, aiming to improve precise and safe delivery to target organs and cells.
- Which investors participated in the August 2022 funding round?
- In August 2022, NGT HealthCare II participated in a funding round for Barcode Nanotech.
- What was a key investment in June 2017?
- In June 2017, NGT3 and Israel Innovation Authority invested in Barcode Nanotech.
- What is Barcode Nanotech's total capital raised?
- Barcode Nanotech has raised a total of $7.6M across its funding rounds.